Mean hemoglobin levels of Roxadustat and ESAs groups over time. by Jie Liu (15128)

Subjects:

Fig 4 - by Maryann S. Watson (16879881)

Subjects:

Morisky score for ESAs group and Roxadustat group. by Jie Liu (15128)

Subjects:

Other robustness test regression results. by Qi Zhang (28502)

Subjects:

Species counts for all trap (kubben) catches across sites and seasons. by Maryann S. Watson (16879881)

Subjects:

Fig 5 - by Maryann S. Watson (16879881)

Subjects:

Association between current exposure to anti-rheumatic agents and ischemic stroke, with non-exposure and past exposure to each anti-rheumatic agent as reference. by Soo Min Ahn (10333246)

Subjects:

Species counts per catch for all fyke catches across sites and seasons. by Maryann S. Watson (16879881)

Subjects:

Baseline regression results. by Qi Zhang (28502)

Subjects:

Study population selection. by Soo Min Ahn (10333246)

Subjects:

Baseline characteristics of cases and controls. by Soo Min Ahn (10333246)

Subjects:

Risk of ischemic stroke according to the use of each anti-rheumatic agents. by Soo Min Ahn (10333246)

Subjects:

Univariate analysis results. by Qi Zhang (28502)

Subjects:

Patient flow diagram. by Jie Liu (15128)

Subjects:

Regression results for heterogeneity in corporate life cycle. by Qi Zhang (28502)

Subjects:

Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup. by Jie Liu (15128)

Subjects:

Fig 2 - by Maryann S. Watson (16879881)

Subjects:

Regression results of mechanism analysis. by Qi Zhang (28502)

Subjects:

Species and numbers of individuals caught on reef-cages and in reference traps. by Maryann S. Watson (16879881)

Subjects:

Summary of clinical outcomes after 9 months. by Jie Liu (15128)

Subjects: